Organisation structure (As of June 2023)

Elected Board

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dale Goldhawk</td>
<td>Chair, Canada</td>
</tr>
<tr>
<td>Andrew Ketteringham</td>
<td>Vice Chair, UK</td>
</tr>
<tr>
<td>John Grosvenor</td>
<td>Treasurer, UK</td>
</tr>
<tr>
<td>Alireza Atri</td>
<td>Medical and Scientific Advisory Panel Chair, USA</td>
</tr>
<tr>
<td>Paul Attea</td>
<td>USA</td>
</tr>
<tr>
<td>Rosa Farres</td>
<td>Mexico</td>
</tr>
<tr>
<td>Emily Ong</td>
<td>Singapore</td>
</tr>
<tr>
<td>Meera Pattabiraman</td>
<td>India</td>
</tr>
<tr>
<td>Jesús Rodrigo Ramos</td>
<td>Spain</td>
</tr>
<tr>
<td>Ameenah Sorefan</td>
<td>Mauritius</td>
</tr>
<tr>
<td>Huali Wang</td>
<td>China</td>
</tr>
</tbody>
</table>

Honorary President

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Princess Yasmin Aga Khan</td>
<td>USA</td>
</tr>
</tbody>
</table>

Honorary Vice Presidents

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Daisy Acosta</td>
<td>Dominican Republic</td>
</tr>
<tr>
<td>Prof Henry Brodaty</td>
<td>Australia</td>
</tr>
<tr>
<td>Mrs Wendy Fleming</td>
<td>New Zealand</td>
</tr>
<tr>
<td>Dr Nori Graham</td>
<td>UK</td>
</tr>
<tr>
<td>Mr Brian Moss</td>
<td>Australia</td>
</tr>
<tr>
<td>Mr Glenn Rees</td>
<td>Australia</td>
</tr>
</tbody>
</table>

Staff

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paola Barbarino</td>
<td>CEO</td>
</tr>
<tr>
<td>Diego Aguilar</td>
<td>Head of Development for the Americas</td>
</tr>
<tr>
<td>Manpreet Arora</td>
<td>Finance Officer</td>
</tr>
<tr>
<td>Lewis Arthorton</td>
<td>Policy and Communications Manager</td>
</tr>
<tr>
<td>Laura Aubert</td>
<td>Membership Manager and Membership Development Lead</td>
</tr>
<tr>
<td>Nikki Bayliss</td>
<td>Head of Development</td>
</tr>
<tr>
<td>Cléo Bеноист</td>
<td>Publications Manager</td>
</tr>
<tr>
<td>Jane Czibor</td>
<td>Head of Events</td>
</tr>
<tr>
<td>Amalia Fonk-Utomo</td>
<td>Head of Accreditation</td>
</tr>
<tr>
<td>Rosie Houghton</td>
<td>Corporate Partnerships Account Manager</td>
</tr>
<tr>
<td>Nick House</td>
<td>Corporate Partnerships Development Manager</td>
</tr>
<tr>
<td>Michael Lefevre</td>
<td>General Manager</td>
</tr>
<tr>
<td>Chris Lynch</td>
<td>Deputy CEO and Director of Policy, Communications and Publications</td>
</tr>
<tr>
<td>Isabella McLeod</td>
<td>Office Coordinator</td>
</tr>
<tr>
<td>Taylor Paatalo</td>
<td>Digital Lead</td>
</tr>
<tr>
<td>Irma Rachmatiah</td>
<td>Finance Officer, Asia Pacific Regional Office</td>
</tr>
<tr>
<td>DY Suharya</td>
<td>Regional Director, Asia Pacific Regional Office</td>
</tr>
<tr>
<td>Wendy Weidner</td>
<td>Head of Research and Publications</td>
</tr>
</tbody>
</table>

Thank you to our donors

- Anonymous Trust
- AbbVie
- Acadia
- Alector
- Bader Philanthropies, Inc.
- Biogen
- Eisai
- GE Healthcare
- GT Diagnostics
- Home Instead
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- Eli Lilly and Company
- H Lundbeck A/S
- The Mary Oakley Foundation, Inc.
- MSD
- Novartis International AG
- Novo Nordisk
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Pharmaceutical Researchers and Manufacturers of America (PhRMA)
- Prothena
- Diane and Dan Riccio
- Roche
- STEP Private Client Awards
- Tunstall Health
- Qatar Foundation
- The Van Otterloo Family

Front cover: ADI CEO Paola Barbarino and Deputy CEO Chris Lynch attended the G7 health ministers meeting in Nagasaki Japan in May 2023.
Chair's report

It is my distinct pleasure to present Alzheimer’s Disease International’s annual report for the 2022-2023 financial year. ADI is the independent global voice on dementia, now in its 39th year, headquartered in London, England, and supports associations in 120 countries around the world.

ADI came to life in 1984 with the forward-thinking, patience, and compassion of hard-working advocates in four founding countries: Britain, the United States, Canada, and Australia.

Back then, those early champions knew that fear and shame played major roles in awareness of dementia and Alzheimer’s, impacting the likelihood of people seeking diagnosis and receiving adequate care and support.

We have since come a very long way.

After years of constant efforts by ADI, the World Health Organization asked its member states in 2017 to commit to the Global action plan on dementia by establishing national strategies to address the growing challenges of dementia. But the world, distracted by COVID-19, military invasions, natural disasters, and endemic poverty, has been slow to react.

In January 2023, ADI launched its first regional #WhatsYourPlan campaign in the Caribbean. The campaign involved 13 ADI member associations and used official letter writing, social media, and traditional media to highlight government inaction and encourage public support. The result: five responses from ministries of health and three commitments to develop national dementia plans. Now it is spreading around the world, and ADI is leading the way by campaigning to have the Global action plan extended to 2029.

Like each September, ADI organized the World Alzheimer’s Month campaign. In 2022, the theme was “Know Dementia, Know Alzheimer’s” and centred around the importance of post-diagnosis support for those living with dementia and their carers. In most parts of the world, that support is in short supply, if available at all.

The ADI Accreditation program was launched in 2020, but really took off in 2022. First to join was Kiang Wu Nursing College of Macau, followed by Silverado Senior Living Memory Care in Irvine, California. Meanwhile, ADI expanded its outreach to Latin America in 2022, with Diego Aguilar joining the team as head of development for the Americas.

So on behalf of the Board of Directors, I invite you to read CEO Paola Barbarino’s exciting introduction – and then carry on to the report itself, with all the details of our successes and challenges. It is proof positive of the growth and influence of ADI, speaking with a compelling voice on behalf of the Alzheimer family around the world.

Dale Goldhawk
What an interesting year 2022/23 has been. A year of growth, development, and reflection. We have been busy on so many counts, and the team has faced requests for engagement and involvement like never before. This is my chance to list the greatest achievements from my perspective, but there have been so many!

Let’s start in order. The 2022 World Alzheimer Report on post-diagnostic support received rave reviews and its webinars smashed all our records of attendance. The new fireside chat webinar series was also a resounding success. The What’s Your Plan Campaign went into its second, mediatic, phase, tackling countries where our diplomatic overtures vis-a-vis the implementation of national dementia plans had fallen on deaf ears. The results were astounding (you will read more in the report), with several countries committing to developing a plan. We also realised that the targets of the World Health Organization (WHO) Global Dementia Action Plan would not be met on time and started campaigning for its extension. This will be essential if we want less wealthy nations to have a chance of developing a plan. In 2022/3 only two new plans, Uruguay and Armenia, were launched.

I was invited to speak by the Government of Japan at the Dementia Symposium during the Health Ministers’ meeting at the G7 in Nagasaki. This was a wonderful opportunity to talk about the issues that matter most to us: for example, how prioritising dementia in policy is critical to help people living with dementia and their families live better lives; how wealthy nations can serve as an example and help less affluent ones; and how healthcare staffing shortages and migration patterns are affecting us all globally. It was also wonderful to have our members, the Alzheimer’s Association (US) and Alzheimer’s Society (UK), with us on this platform, as it magnified our voices and opinions. The subsequent declaration was a success, although we are still monitoring its implementation.

A lot happened in new therapies in this period. Leqembi was approved by the Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), making it the first therapeutic to be reimbursed in the United States, with other nations following suit. Beyond debates regarding safety, suitability, and efficacy, this gave our sector an immense boost, with more researchers and companies running to crowd our space. This is something we had been dreaming about for a long time – only by having multiple teams working on a cure will we ever hope to find one! Whilst we were very active in this debate on a number of fronts, we also managed to apply to list donepezil on the list of Essential Medicines of the WHO. This was a costly, and ultimately unsuccessful, exercise, but absolutely necessary in light of this medicine’s scarcity in conflict and emergency situations and its high cost in Africa.

Meanwhile, our accreditation programme is almost three years old and has grown in leaps and bounds, establishing itself very quickly as the benchmark in its field. A wonderful result!

We continued to be very involved in many areas aside from dementia and Alzheimer’s, with contributions in the fields of non-communicable diseases, neurology, mental health, and healthy ageing. We also signed an agreement with the Ageing Department at the World Health Organization, in addition to our existing one with the Department of Mental Health and Substance Use.

In 2022, we started travelling again. It was wonderful to finally hug so many of our members in person and to better understand what is happening at the country level – including how much havoc COVID-19 has wreaked in different areas of the world, often at the detriment of dementia policy and financing, and, more importantly, of people living with dementia.

Finally, a few of our lovely colleagues left (our events manager of five years, Katie Bingham, and office coordinator Isabella McLeod), but even more joined. We have moved to a small but delightful new office in London. Come see us when you are passing by and share your stories with us!

Paola Barbarino
ADI member associations (As of June 2023)

Argentina
Asociación Lucha contra el Mal de Alzheimer (ALMA)

Armenia
Alzheimer’s Care Armenia

Australia
Dementia Australia

Austria
Demenz Selbsthilfe Austria

Barbados
Barbados Alzheimer’s Association

Belgium
Ligue Nationale Alzheimer Liga ASBL/vzw/VGG (LINAL)

Bermuda
Action on Alzheimer’s & Dementia (AAD) Bermuda

Bolivia
Asociación Alzheimer Bolivia (AAB)

Bonaire
Fundashon Alzheimer Bonaire

Bosnia and Herzegovina
Alzheimer Udruženje AIR – Bosnja Herzegovina

Brazil
FEERAZ – Federação Brasileira de Associações de Alzheimer

British Virgin Islands
Virgin Islands Alzheimer’s Association

Brunei
Demensia Brunei

Bulgaria
Foundation Compassion Alzheimer Bulgaria

Cameroon
Association Comprendre la Maladie d’Alzheimer (ACMA)

Canada
Alzheimer Society of Canada

Cayman Islands
Alzheimer’s and Dementia Association of the Cayman Islands

Chile
Corporación Alzheimer Chile

Côte d’Ivoire
Association des Associations de Maladies d’Alzheimer et de la Personne Aînée d’Ivoire

Colombia
Asociación Colombiana de Alzheimer y Otras Demencias (ALZDECOLOMBIA)

Costa Rica
Asociación Costarricense de Alzheimer y Otras Demencias Asociadas (ASCADA)

Croatia
Alzheimer Croatia (Hrvatska udružba za Alzheimerovu bolest)

Cuba
Sección Cubana de la Enfermedad de Alzheimer

Curaçao
Stichting Alzheimer Curaçao

Cyprus
The Cyprus Alzheimer Association and Related Disorders, Forget-Me-Not

Czech Republic
Ceska alzheimerovska spolecnost

Denmark
Alzheimerforeningen Denmark

Dominican Republic
Asociación Dominicana de Alzheimer

Ecuador
Fundación TASE

Egypt
Egyptian Alzheimer Society

El Salvador
Asociación de Familiares Alzheimer de El Salvador

England, Wales, NI
Alzheimer’s Society

Finland
Alzheimer Society of Finland

France
France Alzheimer & Maladies Apparentes

Georgia
Georgian Alzheimer’s Association

Germany
Deutsche Alzheimer Gesellschaft

Ghana
Alzheimer’s and Related Disorders Society of Ghana

Gibraltar
The Gibraltar Alzheimer’s and Dementia Society

Greece
Panhellenic Federation of Alzheimer’s Disease and Related Disorders

Guatemala
Asociación ERMITA, Alzheimer de Guatemala

Honduras
Asociación Hondureña de Alzheimer

Hong Kong SAR China
Hong Kong Alzheimer’s Disease Association

India
Alzheimer’s & Related Disorders Society of India (ARDSI)

Indonesia
Alzheimer’s Indonesia

Iran
Iran Dementia & Alzheimer’s Association

Ireland
The Alzheimer Society of Ireland

Israel
EMDA – Alzheimer’s Association of Israel

Italy
Federazione Alzheimer Italia

Jamaica
Alzheimer’s Jamaica

Japan
Alzheimer’s Association Japan

Jordan
Al Un For Alzheimer’s Patient Care Association

Kenya
Alzheimer’s & Dementia Organisation Kenya (ADOK)

Lebanon
Alzheimer’s Association Lebanon

Lesotho
Dementia Lesotho

Macau SAR China
Macau Alzheimer’s Disease Association (MADA)

Madagascar
ONG Madagascar Alzheimer – Masaandro Mody

Malaysia
Alzheimer’s Disease Foundation Malaysia (ADFM)

Maldives
Alzheimer’s Society Of Maldives

Malta
Malta Dementia Society

Mauritius
Association Alzheimer & Dementia Mauritius

Mexico
Federación Mexicana de Alzheimer, A.C. (FEDMA)

Montenegro
NVO Futura

Morocco
Association Maroc Alzheimer (AMA)

Myanmar
Alzheimer’s Association Myanmar

Nepal
Alzheimer and Related Dementia Society – Nepal

Netherlands
Alzheimer Nederland

New Zealand
Alzheimers New Zealand

Nicaragua
Fundación Alzheimer de Nicaragua (FADEN)

Nigeria
Alzheimer’s Disease Association of Nigeria (ADAN)

Norway
Nasjonalforeningen for folkehelsen – Norway

Oman
Oman Alzheimer’s Committee

Pakistan
Alzheimer’s Pakistan

Peru
APEAD – Asociación Peruana de Enfermedad de Alzheimer y otras Demencias

Philippines
Alzheimer’s Disease Association of the Philippines (ADAP)

Poland
Polish Society of Alzheimer’s Disease

Puerto Rico
Asociación de Alzheimer y Enfermedades Neurocognitivas de Puerto Rico

Qatar
Qatar Alzheimer’s Society

Romania
Romanian Alzheimer Society

Russia
Foundation Azur

Saudi Arabia
Saudi Alzheimer’s Disease Association

Scotland
Alzheimer Scotland

Singapore
Dementia Singapore

Sint Maarten
Sint Maarten Alzheimer Foundation

Slovak Republic
Slovenska Alzheimerova spolocnost

Slovenia
Spominciča – Alzheimer Slovenija

South Africa
Association for Dementia and Alzheimer’s of South Africa NPC (ADASA)

Spain
Confederación Española de Familiares de Enfermos de Alzheimer (CEFA)

Sri Lanka
Lanka Alzheimer’s Foundation

St Kitts and Nevis
Alzheimer’s Association of St. Kitts and Nevis

Suriname
Stichting Alzheimer en Overige Dementieen Suriname

TADA Chinese Taipei
TADA

Thailand
Alzheimer’s and Related Disorders Association of Thailand

The Bahamas
The Bahamas Alzheimer’s Association

Tonga
Huelo Alzheimer’s Tonga

Trinidad and Tobago
Alzheimer’s Association of Trinidad and Tobago

Tunisia
Association Alzheimer Tunisie

Turkey
Turkish Alzheimer Association

Uganda
Uganda Alzheimer Association

United Arab Emirates
4get-me-not Alzheimer’s Organization – UAE

United States
Alzheimer’s Association

Uruguay
Asociación Uruguay de Alzheimer y Similares

Venezuela
Fundación Alzheimer de Venezuela

Yemen
Yemen Foundation against Alzheimer Dementia (YFAD)

Zimbabwe
Zimbabwe Alzheimer’s and Related Disorders Association (ZARDA)

ADI membership development programme

Azerbaijan
Azerbaijan Alzheimer's Association

Bangladesh
Dementia Care Foundation Bangladesh

Burundi
Alzheimer Community Support of Burundi (ACSB)

Dominica
Dominica Dementia Foundation

Estonia
NGO Living with Dementia

Ethiopia
Alzheimer’s Ethiopia

Grenada
Grenada Alzheimer’s Association

Lithuania
Dementia Lithuania

Malta
Association Comprendre la Maladie d’Alzheimer (ACMA)

North Macedonia
Institute for Alzheimer’s Disease and Neuroscience – North Macedonia

Panama
Asociación de Apoyo a los Familiares de Pacientes con Alzheimer y Otras Enfermedades Demenciales (ARDAPEFA)

Portugal
Obras Sociais Viseu

Senegal
Association Nationale Maladie d’Alzheimer et autres pathologies neuroévolutive (ANAMAN)

Seychelles
Seychelles Alzheimer’s Foundation

Sweden
Demensförbundet

Ukraine
Niezabudni Foundation

Zambia
Alzheimer’s Disease and Related Dementias in Zambia (ADRDZ)
Global voice on dementia in over 100 countries
As the world adjusts to a post-COVID-19 era, new and equally challenging difficulties continue to affect those living with dementia and carers. The effects of the ongoing conflict in Ukraine and recent earthquakes in Syria and Turkey are well documented. In other parts of the world, civil unrest and economic hardship further hamper efforts to ensure that effective dementia policy is implemented. Sadly, there is also a general apathy for dementia globally, with most WHO Member States still not compliant with their 2017 commitment to the Global Action Plan on the public health response to dementia.

**G7 Japan**

Despite previous challenges with securing the attention of governments and civil society during G7 and G20 meetings, Japan’s presidency of the G7 was an unmitigated success for dementia policy and advocacy. Following substantive efforts, which encompassed ADI’s leadership, policy and communications, regional directors, and membership teams, alongside ADI Member Alzheimer’s Association Japan (AAJ), dementia was included in the G7 Health Ministers and G7 leaders’ communiqué, including a direct call for all WHO Member States to adopt National Dementia Plans. Paola Barbarino and Chris Lynch were invited to participate in a rare official health ministers side event, dedicated solely to addressing the global public health crisis that dementia presents.

Paola presented ADI’s work and call to action to the seven health ministers and their representatives in attendance.

**#WhatsYourPlan**

ADI has remained steadfast in its advocacy efforts, having directly influenced the course of dementia policy in several strategic areas. The #WhatsYourPlan campaign has remained an indispensable tool for holding Member States accountable for their commitment to the Global Action Plan. In January 2023, ADI launched its first regional #WhatsYourPlan campaign in the Caribbean. The campaign involved 13 ADI member associations and used official letter writing, social media, and traditional media to highlight government inaction, mobilise public support, encourage sharing of best practices, and inject momentum into plan commitment and development. The campaign resulted in five responses from Ministries of Health and three commitments to develop a National Dementia Plan. Paola presented ADI’s work and call to action to the seven health ministers and their representatives in attendance.

**From Plan to Impact VI**

With just two years remaining until the end of the Global Action Plan on Dementia, ADI called on Member States to push to extend the plan. Through analysis contained within the From Plan to Impact VI report and the World Health Organization’s interim progress report at the World Health Assembly, it is patently clear that Member States are not on track to meet the targets of the Global Action Plan by 2025. In calling for an extension, ADI is all too aware that our advocacy efforts need to further increase, in light of the impact of new treatments and diagnostics on healthcare systems, delays and inequitable access globally, and the urgent need for National Dementia Plans to robustly tackle these challenges, both pre- and post-diagnosis.

**Non-communicable disease challenges**

ADI has challenged the ongoing exclusion of dementia from non-communicable disease (NCD) frameworks, following its absence from WHO and Member States reports and reporting cycles. Addressing this issue is paramount, not least because the current global interest in NCDs provides both financial and political capital. ADI has been engaging with relevant stakeholders to address this issue and has formally written to the director general of the World Health Organization, Dr Tedros Adhanom Ghebreyesus, to express these concerns. He has requested a meeting with ADI, and we are awaiting further details from his office.
Publications are a key means through which ADI establishes itself in the fields of dementia policy, research, awareness, and communications.


Entitled *Life after diagnosis: Navigating treatment, care and support*, the report explores the many facets of life for people with dementia, their carers, and healthcare professionals following a diagnosis of dementia through 119 essays across 24 chapters. The report reflects Action Area 4 of the WHO Global Action Plan, the largest and most complex area. During the World Alzheimer Report webinars, we explored the importance of the inclusion of new and emerging disease-modifying treatments in a holistic post-diagnostic approach, and strongly recommended the need for an identified ‘navigator’ to support people through the post-diagnosis period, and for clinicians and healthcare professionals to become integral parts of the required post-diagnosis team.
Each September, ADI organises the World Alzheimer’s Month campaign, which seeks to challenge the stigma that still exists around the condition. The 2022 campaign marked the 11th year of this vital awareness initiative. Each year, the campaign is centred around a theme, and since 2017 these have reflected the seven action areas of the Global Action Plan on the public health response to dementia.

The theme for the 2022 World Alzheimer’s Month campaign was “Know Dementia, Know Alzheimer’s”, centred around the importance of post-diagnosis support for those living with dementia and their carers. In most parts of the world, post-diagnostic support is sorely lacking, if available at all. Accordingly, the campaign advocated for better provisions for those living with dementia and highlighted best practices in care and support. The campaign was particularly topical given the recent emergence of the first disease-modifying therapies for Alzheimer’s disease seeking regulatory approval in the US, Japan, the European Union, and greater European Economic Area.

Campaign messages were shared across social media using assets that had undergone an extensive refresh. Individual animated graphics corresponding to the warning signs of dementia and 12 risk factors were developed and translated into over 35 languages. ADI also put together two templated traditional media press releases for its member associations – the first with a focus on the Institute of Health Metrics and Evaluation country prevalence data, and the second highlighting key findings from the World Alzheimer Report. ADI member associations excelled once again, not only in their work on social media and in traditional media, but also in lighting up landmarks to raise awareness – most notably Petra and the Amman Citadel (Jordan); Big Ben Clock Tower Replica (India); Edinburgh Castle (United Kingdom); Marina Bay Sands (Singapore); Puente de la Mujer (Argentina), and Podgorica Bridge (Montenegro).

ADI was pleased to welcome its first cohort of digital interns to participate in the campaign. The scheme, which included six interns from around the world (India, Brazil, Switzerland, Hong Kong SAR, and Mauritius), created and amplified messaging, including creatives (animations, illustrations, and videos), around the key campaign themes.

Key figures from World Alzheimer’s Month 2022

- 111 countries participated
- Combined social media reach of 35 million
- 300 pieces of traditional media coverage
This year, ADI’s webinars shed light on some of the latest developments in post-diagnosis treatment, care, and support. Two webinars highlighted key findings from the World Alzheimer Report 2022, with authors, co-authors, and essayists sharing key results and recommendations. Two fireside chats looked into the present and future of pharmaceutical treatments for dementia.

The hybrid launch of the From Plan to Impact VI report took place at a World Health Assembly (WHA) side event in Geneva, Switzerland, with attendees tuning in both in person and online.

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 September 2022</td>
<td>World Alzheimer Report 2022 launch – Life after diagnosis: Navigating treatment, care and support</td>
<td>1,049</td>
</tr>
<tr>
<td>16 February 2023</td>
<td>ADI fireside chat: Drug treatments and therapies for dementia</td>
<td>539</td>
</tr>
<tr>
<td>24 May 2023</td>
<td>WHA Side Event: From Plan to Impact VI report launch</td>
<td>617</td>
</tr>
<tr>
<td>28 June 2023</td>
<td>ADI fireside chat: The future of vaccines for Alzheimer’s and dementia</td>
<td>401</td>
</tr>
</tbody>
</table>

Paola Barbarino and Dr Alireza Atri during the fireside chat on drug treatments and therapies for dementia on 16 February 2022.
Dementia Alliance International (DAI) was thrilled to celebrate its ninth birthday on 1 January 2023, and to have been working in collaboration with ADI for the past eight years, a partnership in which DAI is the global voice of people with dementia, and ADI is the global voice on dementia. We are also grateful for our strategic partnership with one of ADI’s member associations, Dementia Australia. These relationships are important, as they have enabled DAI to continue striving to improve the quality of life of all people with dementia and their families.

The year saw a number of changes for DAI and its board. At our annual general meeting held in July, members unanimously indicated that they wanted DAI to continue as a member organisation for people living with dementia and keep holding online peer-to-peer support groups. In order to enable this, it was decided to include a minority of people who do not have dementia on the Board of Directors to assist with DAI governance and operations. The Board of Directors currently includes Alister Robertson (Chair), Bill Yeates (Vice Chair), Janine Whited, and Kate Swaffer. Non-Executive Directors (people who do not have dementia) are Patricia Bowen (Treasurer), Gary Johnson, and Jacqueline Wong.

DAI has decided to cease its webinar series – however, past webinars remain available on our YouTube channel, while past blog posts can be accessed on our website.

The DAI Environmental Design Special Interest Group for accreditation

The Environmental Design Special Interest Group (ED-SIG) has been actively meeting bimonthly and working on four objectives identified in the ADI World Alzheimer Report 2020.

The Richard Taylor 2022 Advocates Award

On World Alzheimer’s Day, DAI was delighted to announce that the prestigious Dr Richard Taylor Advocates Award went to Dr Jennifer Bute. Based in the United Kingdom, she has worked tirelessly to advocate for other people living with dementia, having herself been diagnosed in 2009. Like so many of our members, Jennifer thought her diagnosis was the end, then discovered it was not! That is exactly what DAI does for its new members: it brings back hope and a renewed sense of purpose.

The compilation of recommended resources to support environment design has completed Phase 1 and is now available on the DAI website.


In the field of membership support and development, ADI has been dedicated to nurturing Alzheimer and dementia associations across the world, going beyond mere resource provision to empower our members in the pursuit of their mission.

One of our standout initiatives each year is the Alzheimer University training programme. In October 2022, we hosted a three-day Alzheimer University in London, UK, welcoming participants from Azerbaijan, Dominica, Ethiopia, North Macedonia, Seychelles, Sweden, and Ukraine. The event was an impactful experience, setting the stage for a follow-up session in April 2023 to gauge progress. On 25 October 2022, Paola delivered a half-day Alzheimer University under Chatham House Rules on how to work with multilateral organisations for 10 Latin-American associations in Montevideo, Uruguay.

Regional meetings have played a vital role in fostering collaboration and growth. ADI’s Asia Pacific regional members gathered in Taipei in December 2022, for a pivotal meeting. In the Caribbean, four online regional discussions unfolded, addressing topics such as Working with churches in the Caribbean and How to build your own website. Meanwhile, in Thessaloniki, Greece, a #WhatsYourPlan workshop united 21 participants from 13 European countries. The Middle East was not left out, as an online regional meeting brought together 12 representatives from eight member associations.

Member webinars are where experiences are shared and bonds are strengthened. A New Year’s member webinar in January 2023 drew 53 participants from 42 countries, emphasising our global reach. Spanish-speaking associations received a special follow-up webinar in January, with 17 participants from 15 countries. We further discussed the impact of the Caribbean #WhatsYourPlan regional campaign in a member coffee catch-up in February 2023, with 35 participants from 28 countries.

The ADI/GBHI webinar titled “Better Together: Increasing impact on brain health equity through partnership” was a resounding success, attracting over 123 participants from around the world.

Council meetings are a cornerstone of ADI’s governance. The online council meeting in June 2023 saw 96 participants, including 69 representatives from 56 member associations, eight from the Membership Development Programme, 14 ADI staff members, and three ADI board members, as well as ADI Honorary Vice President Nori Graham and Jean Georges of Alzheimer Europe.

Lastly, our Francophone meetings have set the stage for future endeavours. A Francophone roundtable in March 2023 initiated discussions about the first-ever ADI Francophone Day in Nairobi, Kenya, scheduled for November 2023 after the 5th Africa Regional Conference of Alzheimer’s Disease International.
Regional updates

Asia Pacific

ADI's Asia Pacific Regional Office (APRO) has laid the foundations for more than 20 members in the region to become strong and self-reliant, allowing them to face the challenges of improving the quality of life for people with dementia and carers in their respective countries. This has been made possible since 2013 with the support of our anonymous donor.

The year 2022 was one of high-profile, in-person advocacy meetings including with Indonesian Minister of Health Budi Gunadi Sadikin, Malaysia Minister of Health Khairy Jamaluddin and Dr Zalihah Mustafa Jamaluddin, Maldives Minister of Health Dr Ahmed Naseem and Vice President Faisal Naseem, Maldives Department of Health Mental Health Division Team, and Chinese Taipei Director Department of Long Term Care Ministry of Health Chien Fang Chu. These high-level meetings resulted in each of these six countries making stronger commitments to developing or strengthening their national dementia plans.

ADI Asia Pacific Regional Director DY Suharya was appointed as the Wellbeing Task Force Leader of Values 20 and facilitated the policy writing session with all V20 members, advocating for the importance of including dementia in policy papers that were launched in October 2022 in Bali, Indonesia. DY also took part in the C7 summit in Japan in May 2023.

ADI APRO also had the chance to strengthen its partnerships with the Asian Development Bank, the World Health Organization’s South-East Asia (SEARO) and Western Pacific (WPRO) regional offices. DY was invited to take part in the WHO Dementia Research Blueprint launch in October 2022, which brought together academics and researchers from around the world to coordinate their efforts into dementia innovation.

In September 2022, DY was chosen as one of the 50 UN Decade Healthy Ageing Leaders, an initiative led by the UN in collaboration with the WHO. Prior to that, Ageing Asia had recognised DY as the Global Healthy Ageing Influencer of the year.

Latin America and the Caribbean

With Diego Aguilar joining the ADI family this year as Regional Director for the Americas, ADI has been able to strengthen and expand its activities in the region.

In a region where age and poverty are the biggest risk factors for dementia, it has been truly powerful to observe our members’ work. Yet, despite their efforts to raise awareness, only eight countries in the region have consolidated dementia plans, many unfunded. Many governments are still ignoring dementia in this rapidly ageing region, even though the clock is ticking on the WHO Global Action Plan on the public health response to dementia, which is due to end in 2025.

The majority of countries in Latin America and the Caribbean have adopted the ‘society of care’ approach in the framework of the Montevideo Consensus and the recent Buenos Aires Commitment to promote care policy in the region, but tangible results remain scarce. Yet this year has given us some hope for change. Uruguay has had wonderful news. In October, ADI CEO Paola Barbarino and part of the team travelled to Montevideo and met with Uruguay’s Minister of Health to discuss the significance of implementing a plan. With the help of local member AUDAS, this meeting led to the launch of a cutting-edge National Dementia Plan in March, serving as a guiding light in the Southern Cone.

While ADI’s Latin American and Caribbean members are diverse, there is no doubt that they are united. Across the region, hundreds of volunteers and advocates have organised marathons, cooking challenges, webinars, in-person conferences, TV interviews, and digital campaigns. We have also grown. Argentinian member ALMA has consolidated its regional expansion policy with RADA, a network of 19 associations spread throughout the country. FEDMA has also strengthened its network from North to South.

DY Suharya and Noriyo Washizu were at the C7 Summit in Tokyo in April.

Diego Aguilar, Paola Barbarino, and Laura Aubert from ADI meet with Uruguay Minister of Health Daniel Salinas, and health officials Ignacio Amorín and Gustavo Gaye in October 2022.
Launched in December 2020, the ADI Accreditation programme was built with the aim of creating a standard of quality for dementia care education after repeated requests for ADI to endorse certain dementia-related training programmes.

Accreditation not only represents a formal acknowledgment of good practices, but also a reflection of our commitment to collaboration with ADI partners, aimed at mutual growth and the advancement of dementia education for a brighter future.

ADI’s Accreditation programme properly took off in 2022, collaborating with several leading global training providers and organisations.

Silverado Senior Living Memory Care in Irvine, California, USA was the second programme accredited by ADI (after Kiang Wu Nursing College of Macau earlier in the year). A first in-person visit took place in August 2022, and on 13 December 2022, the organisation was officially accredited in a virtual ceremony.

“Our goal is to change the world of dementia care by providing excellent training materials that focus on person-centred care,” said Loren Shook, co-founder, president, CEO, and chairman of Silverado. “As a part of the ADI Accreditation family, we look forward to continuing to improve the lives of people with dementia and their loved ones in the months and years to come.”

In June 2023, ADI carried out an in-person visit to the Centre of Applied Dementia Studies (CiADS) at the University of Bradford in the UK, with a virtual accreditation ceremony planned for November 2023.

“The way all approached the process, your supportive questioning and feedback made the ADI Accreditation a simply wonderful experience,” Professor Karen Windle said of the University of Bradford’s experience. “It also gave the CiADS team some (much needed) space to look back at the work that they’ve done, as well as forward to what we want to achieve.”

Other applicants are also in the process of accreditation, including the Wicking Dementia Research and Education Centre at the University of Tasmania in Australia; and Dementia Australia.

The ADI Accreditation programme continues to expand its visibility, whether at global and regional conferences, other events, or on social media.

“ADI’s Accreditation programme properly took off in 2022, collaborating with several leading global training providers and organisations.”
Medical and Scientific Advisory Panel (MSAP)

ADI’s Medical and Scientific Advisory Panel, a 100-strong group of dementia experts, provided invaluable expertise this year on the importance of including dementia among non-communicable diseases, as well as making valuable contributions to ADI publications such as the World Alzheimer Report.

Essential Medicines List (EML)

Professor Dame Louise Robinson, MSAP’s new co-chair, led a working group that assisted ADI in preparing an application for the inclusion of dementia medications on the World Health Organization’s Essential Medicines List, submitted with Newcastle University and the London School of Economics (LSE), and with important backing from ADI members. While our efforts were unfortunately unsuccessful, the team was able to gather important data and develop strategic alliances to enable us to try again in two years’ time.

New developments in disease-modifying drugs

The approval of Leqembi by the Food and Drug Administration in the US marked an opportunity for ADI to reiterate its calls for equitable access to treatment. This development highlighted the necessity to address health system readiness across the globe to accommodate new medications, a critical issue ADI has long been advocating for.

Nurturing ongoing projects and collaborations

ADI solidified ongoing collaboration with World-Wide FINGERS on multidomain risk reduction and continued fruitful and impactful connections with the Global Brain Health Institute (GBHI) and their fellows. In the spring, ADI participated in the “Walking the Talk for Dementia” supported by Vovô Nilva Institute, CDD Association, GBHI, Atlantic Institute, BrainLat, and Alzheimer's Association. A diverse group of participants, including people living with dementia, carers, clinicians, researchers, policymakers, and care providers, walked the Camino de Santiago de Compostela in Spain before attending a scientific symposium.

In collaboration with ADI and LSE, Lorenzo’s House adapted the STRiDE’s anti-stigma toolkit, ‘Don’t Forget I’m Human’, to address the unique needs of young people coping with a parent with younger-onset dementia. Elsewhere, the IMPACT project in Peru saw ADI work hand in hand with Imperial College London and Universidad Peruana Cayetano Heredia.

A few projects wrapped up, but tools remain, and interest continues...

STRiDE (STrengthening Responses to dementia in DEveloping countries), reached its culmination in 2022. Its conclusion has yielded important publications, including one focused on translating research into policy that saw seven ADI members recognised as authors. ADI also actively contributed to the ‘Don’t forget I’m human’ anti-stigma toolkit.

Another concluded initiative, Cognisance (CO-desiGning demeNtia diagnoSis AND post-diagnostic CarE), led to the creation of the “Forward with Dementia” website. The site aims to enhance the tools available to health and care professionals for diagnosis and post-diagnostic care, and was developed with input from people living with dementia, carers, and healthcare professionals.

Research publications

- ADI (Nikki and Wendy) contributed to the Roche FAST (Finding Alzheimer Solutions Together) Council publication ‘Integrating the perspectives of people living with Alzheimer’s disease and their study partners into clinical trial development’ launched during the Alzheimer Europe conference in Bucharest.
Improving our finances has long been an ADI objective, not just because we prefer to see net surpluses rather than net deficits, but because we have recognised the need to do more to support our members. They face the impact of the growing number of dementia cases around the world and, often, the failure of governments to rise to the challenge. As you can see from the rest of the Annual Report, the ADI team has been highly active in this past financial year to assist their efforts.

I am delighted to say that ADI continues to be in good shape financially in these uncertain times, despite recording a deficit of $130,559. The board had agreed to plan for a deficit to use some of the surplus generated in the previous year. There was a healthy cash balance of $1.3m as of 30 June 2023.

We managed to maintain our level of income. As of 30 June 2023, unrestricted reserves stood at $829,698.

This has enabled us to plan expanding ADI activities in the current financial year; we have increased income in the years to June 2023 by making ourselves the most significant global force fighting dementia. As we continue to enjoy a healthy financial position, we can plan to meet the challenges ahead and make life better for people living with dementia.

I would like to thank all those who have continued to support us: our member associations around the world, who provide crucial financial support as well as being the basis for our global activities; the trusts, foundations, corporations, and individuals that have increased their contribution in recent years, thanks to whom we are able to make significant advances in our endeavour.

Statement of financial position

As of 30 June 2023

Assets

Current Assets

Cash US$ 1,316,716
Accounts receivable 739
Grants and contributions receivable - net 39,952
Current portion of pledges receivable 50,000
Prepaid expenses 30,551
Total current assets 1,437,958

Property and Equipment

Furniture and equipment 78,285
Less: accumulated depreciation (36,627)
Net property and equipment 41,658

Other Assets

ROU asset - operating 100,368
Rent security deposit 27,160
Website development, net of amortization 8,767
Pledge receivable, net of current portion 50,000
Total other assets 186,295

Total assets 1,665,911

Liabilities and Net Assets

Current Liabilities

Accounts payable and accrued liabilities 101,030
Deferred revenue 88,379
Grants payable 67,413
Current portion of operating lease liability 50,000
Total current liabilities 256,822

Long-term Liabilities

Operating lease liability, net of current portion 45,774
Total long-term liabilities 45,774
Total liabilities 302,596

Net Assets

Without donor restrictions 829,698
With donor restrictions 533,617
Total net assets 1,363,315

Total liabilities and net assets US$ 1,665,911
Income and expenses

**Income**

ADI is a 503(c)(3) non-profit organisation, incorporated in the state of Illinois, USA. The figures in this report are for the 2022–23 year, which ended on 30 June 2023.

ADI member Alzheimer associations pay dues according to their own income. ADI also receives contributions and grants from corporations, foundations, trusts, and individuals. ADI also receives support from Friends of ADI, a UK-registered charity. Friends of ADI does not run any programmes of its own – it exists to support the work of ADI.

**Expenses**

ADI’s expenses are classified into six functions: the four main areas of programme work (listed in the “Expenses” chart below), management and administration, and fundraising.

‘Member support and development’ includes Alzheimer University training programmes and other support and advice provided to Alzheimer associations. ‘Promotion and awareness’ includes World Alzheimer’s Month, the Global Perspective newsletter, the ADI website, and ADI staff and Elected Board members taking part in other conferences and meetings to promote our work and our cause. It also includes ADI’s public policy work, such as the World Alzheimer Report. ‘Research’ is ADI’s role in research projects, which is mainly to advise and disseminate. There is a heading for the ADI International conference, although there was no conference during the financial year.

---

**Statement of activities and changes in net assets**

For the Year Ended 30 June 2023

<table>
<thead>
<tr>
<th>Support and Revenue</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dues</td>
<td>508,348</td>
<td>-</td>
<td>508,348</td>
</tr>
<tr>
<td>Contributions and grants</td>
<td>535,998</td>
<td>606,524</td>
<td>1,142,522</td>
</tr>
<tr>
<td>Conference revenue</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Institutional funding</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Accreditation fees</td>
<td>33,469</td>
<td>-</td>
<td>33,469</td>
</tr>
<tr>
<td>Interest and other</td>
<td>2</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>In-kind contributions</td>
<td>535</td>
<td>-</td>
<td>535</td>
</tr>
<tr>
<td>Loss on currency exchange transactions</td>
<td>(19,610)</td>
<td>-</td>
<td>(19,610)</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>700,108</td>
<td>(700,108)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total support and revenue</strong></td>
<td><strong>1,758,850</strong></td>
<td><strong>(93,584)</strong></td>
<td><strong>1,665,266</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program</td>
<td>1,294,843</td>
<td>-</td>
<td>1,294,843</td>
</tr>
<tr>
<td>General and administrative</td>
<td>371,660</td>
<td>-</td>
<td>371,660</td>
</tr>
<tr>
<td>Fund raising</td>
<td>222,906</td>
<td>-</td>
<td>222,906</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>1,889,409</strong></td>
<td>-</td>
<td><strong>1,889,409</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change in net assets</th>
<th>Without Donor Restrictions</th>
<th>With Donor Restrictions</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets, beginning of year</td>
<td>(130,559)</td>
<td>(93,584)</td>
<td>(224,143)</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>960,257</td>
<td>627,201</td>
<td>1,587,458</td>
</tr>
</tbody>
</table>

These figures are extracts from the financial statements which are available in full on www.alzint.org/financials

---

**Income**

- Contributions and grants 69%
- Accreditation 2%
- Membership dues 29%

**Expenses**

- Promotion and awareness 41%
- Member support and development 20%
- General administration 20%
- Fundraising 12%
- Conference 5%
- Research 2%
Our vision is risk reduction, timely diagnosis, care, and inclusion today, and cure tomorrow.

Our mission is to strengthen and support Alzheimer and dementia associations, to raise awareness and lower stigma about dementia worldwide, to make dementia a global health priority, to support and empower people living with dementia and their care partners, and to increase investment and innovation in dementia research.